Skip to content

Clinical study on comprehensive treatment of olfactory dysfunction after COVID-19 infection

Clinical study on comprehensive treatment of olfactory dysfunction after COVID-19 infection

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300069795
Enrollment
Unknown
Registered
2023-03-26
Start date
2023-04-01
Completion date
Unknown
Last updated
2023-05-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

olfactory dysfunction

Interventions

Oral glucocorticoid + hyperbaric oxygen treatment group:hyperbaric oxygen treatment
Oral glucocorticoid + simulated hyperbaric oxygen treatment grou: simulated hyperbaric oxygen treatment group

Sponsors

Xijing Hospital of Air Force Medical University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: (1) Subjects must voluntarily sign informed consent; (2) Age =18 years and =60 years; (3) Decreased or lost sense of smell in olfactory stick test, total TDI score =30; (4) Anosmia occurs within 2 weeks after the diagnosis of COVID-19 infection and lasts for at least 2 weeks, no nasal congestion, runny nose and other upper respiratory symptoms. (5) Ear, nose and throat specialized physical examination, nasal endoscopy, sinus CT and cranial MR did not show sinus and cranial lesions

Exclusion criteria

Exclusion criteria: (1) Those who voluntarily asked to quit had poor compliance and could not cooperate with regular follow-up and treatment observers (2) Subjects have the following medical conditions: chronic sinusitis, asthma, eosinophilia, phantom olfactory or olfactory allergies, cystic fibrosis, congenital ciliary dyskinesia, nasal tumors, nasal facial malformations, history of nasal facial trauma resulting in nasal obstruction, invasive or non-invasive fungal sinusitis, and sinus anatomical abnormalities. (3) a severe metabolic, cardiovascular, immune, neurological, blood, digestive, cerebrovascular, or respiratory disease, accompanied by head trauma, or a disease that the investigator has assessed could affect the study results or the safety of the subject. (4) Patients with a history of craniocerebral and nasal surgery. (5) Pulmonary bullosa, eustachian tube dysfunction, severe cardiopulmonary dysfunction and other hyperbaric oxygen therapy contraindicated patients. (6) Staff members who are currently participating in other clinical studies or have participated in other clinical investigators within 30 days, or are directly involved in such studies. (7) A history of mental illness, antagonistic personality, bad motivation, paranoia, or other emotional or intellectual problems may affect the informed validity of participants in the study. (8) Pregnant and lactating women.

Design outcomes

Primary

MeasureTime frame
SNOT-22;Visual Analogue Scale;Sniffin' Sticks olfactory test (TDI) score;

Countries

China

Contacts

Public ContactFuquan Chen

First Affiliated Hospital of Air Force Medical University

chenfq@fmmu.edu.cn+86 13772079206

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026